This promotional on-demand resource centre has been developed, organised and funded by Lilly in conjunction with the Abracadabra Programme Planning Committee. Lilly Products will be discussed in these videos, and prescribing information is available below. Lilly is a registered trademark of Eli Lilly and Company. © 2025 Eli Lilly and Company. All rights reserved.

These videos are broadcast in association with Diabetes on the net, the Journal of Diabetes Nursing, Pharmacy Notebook and Practice Nurse. The media partners have had no input into the content of this activity.

Prescribing information for Lilly products can be accessed at the following links: Abasaglar® (insulin glargine), Humalog® (insulin lispro),  Lyumjev® (insulin lispro), Mounjaro®▼ (tirzepatide), and Trulicity® (dulaglutide). For more information about Lilly products, please visit https://uk.lilly.com/metabolic/.

Adverse event reporting information is available at the bottom of the page.

A spotlight on personalised and compassionate care for those living with type 2 diabetes and obesity

Watch on demand now

Welcome

Expand your knowledge and skills in type 2 diabetes and obesity management. This Lilly promotional and educational on-demand resource centre aims to provide you with the latest insights into the pathophysiology of type 2 diabetes and obesity, optimal treatment and lifestyle choices, and why the language we choose to use is an integral part of the management process.

HIGHLIGHTS

The latest insights into type 2 diabetes and obesity management

Six educational videos featuring an array of expert speakers

Resources designed to help you improve your knowledge and clinical practice

On-Demand Videos

Spotlight on: Navigating the complexity of obesity and type 2 diabetes dietary intervention

Understanding the pathology of obesity

Dr Matthew Capehorn

  • Obesity prevalence, definition and its associated risk factors for other diseases
  • Obesity pathology and the effects of weight loss
  • Treatment for obesity, lifestyle modification and behaviour change

Diet in diabetes: DiRECT study 5 years on

Professor Roy Taylor

  • How insulin sensitivity effects how energy is stored in the body after a meal
  • The COUNTERPOINT study, which assessed the effects of dieting on type 2 diabetes remission
  • The DiRECT study, which assessed whether diabetes remission could be maintained from dietary weight loss

Spotlight on: Supporting people living with obesity

Weight bias and stigma - Why language matters

Dr Eveleigh Nicholson

  • Guidelines for obesity identification, assessment and management
  • Definition and examples of weight bias and stigma in obesity management
  • Challenges in obesity management and the impact of weight bias and stigma
  • Why language is important in weight and obesity management

The next chapter in weight management

Professor Alex Miras

A Lilly promotional session

  • Indications, molecular structure and pharmcodynamics of Mounjaro® (tirzepatide)
  • The SURMOUNT-1 study and data, which assessed the long-term effects of Mounjaro® (tirzepatide) on weight vs semaglutide
  • Safety data of the SURMOUNT-1 study

Spotlight on: How lifestyle interventions and treatment can help people living with type 2 diabetes

The role of physical activity for people living with type 2 diabetes

Professor Melanie Davies

  • Physical activity: the benefits and why it is important
  • The effects of walking, sweating, sitting, strengthening and sleep in type 2 diabetes - 24‑hour health behaviours
  • Exercise and lean mass preservation
  • How weight loss effects the body

Type 2 diabetes: How can we support people with the use of incretins?

Dr Kevin Fernando

A Lilly promotional session

  • How incretin molecules work in the body to regulate glucose metabolism
  • The SURPASS-2 study, which assesses the effects of Mounjaro® (tirzepatide) on HbA1c and weight vs semaglutide
  • Safety data and prescribing for Mounjaro (tirzepatide)

Speakers

This promotional on-demand resource centre has been developed, organised and funded by Lilly in conjunction with the Abracadabra Programme Planning Committee. Lilly Products will be discussed in these videos, and prescribing information is available below. Lilly is a registered trademark of Eli Lilly and Company. © 2025 Eli Lilly and Company. All rights reserved.

These videos are broadcast in association with Diabetes on the net, the Journal of Diabetes Nursing, Pharmacy Notebook and Practice Nurse. The media partners have had no input into the content of this activity.

Prescribing information for Lilly products can be accessed at the following links: Abasaglar® (insulin glargine), Humalog® (insulin lispro),  Lyumjev® (insulin lispro), Mounjaro®▼ (tirzepatide), and Trulicity® (dulaglutide). For more information about Lilly products, please visit https://uk.lilly.com/metabolic/.

Adverse events and product complaints should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events and product complaints should also be reported to Lilly: please call Lilly on 01256 315 000.

PP-LD-GB-2911 | June 2025